江西泰吉立生物制药

江西泰吉立生物制药 (Jiangxi Taijili Biopharmaceutical) is a Chinese pharmaceutical company specializing in the development, manufacturing, and commercialization of high-end generic drugs and chemical formulations. Established in 2022 and headquartered in Nanchang, Jiangxi Province, the company operates a modern manufacturing facility that produces a variety of injections and solid oral dosages. Its commercial portfolio features sacubitril valsartan sodium tablets for heart failure and hypertension, alongside critical care and vitamin therapies such as vitamin B6 injection, norepinephrine bitartrate injection, dopamine hydrochloride injection, metaraminol bitartrate injection, and calcium gluconate injection. The company continues to expand its pipeline through regulatory submissions for products like furosemide injection and pentoxifylline injection.